ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2952

Differentiation Between Neurosarcoidosis and Primary CNS Vasculitis Based on Clinical and Cerebrospinal Fluid Parameters

Didem Saygin1, Leonard H. Calabrese2, Elisabeth Ray1, William Messner3, Jinny Tavee4 and Rula A Hajj-Ali5, 1Rheumatology, Cleveland Clinic, Cleveland, OH, 2Rheumatic & Immunologic Disease, Cleveland Clinic, Cleveland, OH, 3Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, 4Neuromuscular diseases, Cleveland Clinic, Cleveland, OH, 5Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: CNS Vasculitis, differential diagnosis, neurosarcoidosis and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Vasculitis - Poster III: Rarer Vasculitides

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Neurosarcoidosis is one of the great mimickers of primary angiitis of central nervous system (PACNS) in terms of disease presentation, imaging and pathologic findings. However treatment strategies are different specifically in term of biologics which is rarely used in PACNS.  Therefore, distinguishing these diseases earlier would be important giving the distinct therapeutic implications.   We aimed in this original study to distinguish demographic, cerebrospinal fluid (CSF) and laboratory characteristics of both diseases to enhance our diagnostic approach.

Methods: 79 patients with PACNS and 51 patients with neurosarcoidosis were included in the study. All the clinical, CSF and laboratory characteristics at the time of presentation were retrieved from electronic medical records. For comparisons on the basis of diagnosis, numerical variables were compared between groups using either ANOVA or the Kruskal-Wallis rank-sum test.  Categorical variables were compared between groups using either Pearson’s chi-squared test or Fisher’s exact test.  All analyses were performed using SAS 9.4 software (SAS Institute, Cary, NC).  All testing was two-sided, and considered significant at the 5% level.

Results: Demographic and CSF characteristics, blood CRP, ESR, ANA, RF levels of the patients were shown in the Table. There was a statistically significant difference between diagnoses on two variables.  The first was race, where African American patients tended to be diagnosed with neurosarcoidosis and Caucasian patients tended to be diagnosed with PACNS (p < 0.001).  The second was ANA, where higher levels tended to be associated with neurosarcoidosis (p = 0.047), and lower levels tented to be associated with PACNS.  Although not statistically significant, two other variables showed promise for distinguishing the two diagnoses: total nucleated cells (p = 0.067) and neutrophils (p = 0.14).  Higher values of total nucleated cells showed some tendency toward neurosarcoidosis, whereas low values showed some tendency toward PACNS. Neutrophil counts in the high range tended to correspond to neurosarcoidosis, whereas neutrophil counts in the low range tended to correspond to PACNS (Figure).  

Conclusion: African American race and positive ANA were found to be associated with the diagnosis of neurosarcoidosis rather than PACNS. Total nucleated cells and neutrophil counts in the CSF showed promise in differentiating the neurosarcoidosis and PACNS. A follow-up study with a larger sample size would be required to firmly establish such a relationship. Table. Demographic and CSF characteristics of patients with neurosarcoidosis and PACNS

Total (N=130) PACNS (N=79) Neurosarcoidosis (N=51) p-value
Age at presentation* 43.8±15.0 43.7±16.7 44.0±12.0 0.92
Gender* 0.40
.     Male 70(54.3) 40(51.3) 30(58.8)
.     Female 59(45.7) 38(48.7) 21(41.2)
Race* <0.001
.     Caucasian 110(88.0) 73(97.3) 37(74.0)
.     African American 15(12.0) 2(2.67) 13(26.0)
CSF Glucose* 65.0±27.1 66.6±21.4 62.7±34.3 0.59
CSF Protein* 60.0[37.5,90.5] 59.0[37.0,73.0] 61.0[38.0,133.0] 0.25
CSF Reac Lymph%* 2.0±1.6 2.0±1.7 2.1±1.6 0.88
CSF RBC* 5.0[1.00,46.5] 6.5[0.00,32.0] 3.0[1.00,235.0] 0.47
CSF Neutrophils* 0.14
.     Neutrophils < 40% 23(69.7) 14(82.4) 9(56.3)
.     Neutrophils ≥ 40% 10(30.3) 3(17.6) 7(43.8)
CSF Lymph%* 86.5[57.0,92.5] 85.5[60.0,93.0] 87.0[41.0,91.0] 0.51
CSF Mono%* 7.0[4.0,16.0] 8.0[4.0,16.0] 7.0[4.0,11.0] 0.65
CSF Total nucleated cells* 12.0[2.0,36.0] 8.5[1.00,32.0] 17.0[6.0,50.0] 0.067
ACE/Angiotensin Blood* 28.6±20.2 25.1±19.7 29.9±20.5 0.44
Blood Soluble IL2-R levels* 641.0[425.0,1000.0] 600.5[397.0,722.0] 647.0[458.0,1000.0] 0.84
CRP* 0.60[0.20,3.7] 0.70[0.20,4.9] 0.55[0.15,1.00] 0.41
ESR* 12.5[5.0,28.0] 15.0[5.0,29.0] 8.0[7.0,24.0] 0.61
ANA* 0.30[0.20,0.70] 0.30[0.20,0.50] 0.50[0.30,0.80] 0.047
RF* 7.0[5.0,9.0] 7.0[2.5,9.0] 8.0[7.0,10.0] 0.31
*Data not available for all subjects. Missing values: ACE/Angiotensin Blood = 74, Age at presentation = 3, Glucose = 68, Reac Lymph% = 108, Blood Soluble IL2-R levels = 83, Lymph% = 66, Mono% = 67, Total nucleated cells = 66, Protein = 66, RBC = 66, Gender = 1, Neutrophils = 97.  Additionally, 2 Asian, 1 Arabic, and 2 non-identifying patients are not included the analysis. Values presented as Mean ± SD, Median [P25, P75], or N (column %).

Figure.  Neutrophil Counts in Cerebrospinal fluid and its association with the type of diagnosis.


Disclosure: D. Saygin, None; L. H. Calabrese, BMS, Genentech, Horizon Pharma, Crescendo, Pfizer, GSK, Regeneron, UCB, Abbvie, Jannsen, 5; E. Ray, None; W. Messner, None; J. Tavee, None; R. A. Hajj-Ali, None.

To cite this abstract in AMA style:

Saygin D, Calabrese LH, Ray E, Messner W, Tavee J, Hajj-Ali RA. Differentiation Between Neurosarcoidosis and Primary CNS Vasculitis Based on Clinical and Cerebrospinal Fluid Parameters [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/differentiation-between-neurosarcoidosis-and-primary-cns-vasculitis-based-on-clinical-and-cerebrospinal-fluid-parameters/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differentiation-between-neurosarcoidosis-and-primary-cns-vasculitis-based-on-clinical-and-cerebrospinal-fluid-parameters/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology